Vyome Holdings (HIND) presented results from its preclinical studies investigating VT-1908 for treating uveitis at the recent Annual Meeting of the American Society for Pharmacology and Experimental Therapeutics. In a preclinical model of anterior uveitis, the most common form of uveitis, the twice-daily application of VT-1908 eyedrops significantly reduced the uveitis score. The efficacy of VT-1908 was found to be similar to a clinically used steroid.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIND:
- Vyome Holdings appoints Richard Fahrner as CTO
- Vyome Holdings announces positive interim data from VT-1953 Phase 2 study
- Vyome Holdings Completes Merger with Vyome Therapeutics
- Vyome Holdings, Embryyo Technologies sign MoU for AI-enabled medical devices
- Vyome Holdings Amends Equity Distribution Agreement